Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13149938 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL3099571 | 1.00 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| Hydrochloric Acid SCHEMBL3090994 | 0.98 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| Hydrochloric Acid SCHEMBL1989031 | 0.98 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| Hydrochloric Acid SCHEMBL16763418 | 0.98 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL24593361 | 0.98 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL9470148 | 0.91 | MEN1 (0.40) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| Hydrochloric Acid SCHEMBL9470146 | 0.89 | MEN1 (0.39) | MEN1KMT2AMAPTALDH1A1PPM1B | |
| SCHEMBL30278792 | 0.87 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL1298246 | 0.86 | MAPT (0.50) | MEN1KMT2AMAPTALDH1A1PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | LUPIN LIMITED (IN) | 2025-11-25 | — | — | US | disclosed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| EP-4004002-B1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| CN-114174303-B | Macrocyclic compounds as STING agonists and methods and uses thereof | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-111315734-B | Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists | 克罗诺斯治疗有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | BHATTACHARYA SAMIT KUMAR | 2010-05-13 | — | — | US | disclosed |
| US-7671043-B2 | Cycloalkylamino acid derivatives | PFIZER INC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090227641-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER, INC. | 2009-09-10 | — | — | US | disclosed |
| CN-101384599-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| EP-2021338-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Products Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-1987035-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| WO-2007093515-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN LA-ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | MEN1 1450/4885KMT2A 924/4885MAPT 1028/4885 |
| US-20100120794-A1 | Cycloalkylamino Acid Derivatives | CCND1, CCND2, CCND3 | MEN1 871/4885KMT2A 1433/4885MAPT 3368/4885 |
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | STING1, CGAS, MAVS | MEN1 1550/4885KMT2A 4765/4885MAPT 2326/4885 |
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | MEN1 3909/4885KMT2A 4443/4885MAPT 4306/4885 |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCND1, CCND2, CCND3 | MEN1 871/4885KMT2A 1433/4885MAPT 3368/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | MEN1 2260/4885KMT2A 3088/4885MAPT 2172/4885 |
| US-20090227641-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCNI, CCNA1, PCNA | MEN1 1531/4885KMT2A 1501/4885MAPT 3088/4885 |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | MEN1 1040/4885KMT2A 1082/4885MAPT 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.